Osteopenia and endothelin-1-mediated vasconstrictor tone in postmenopausal women

Bone

Volumn 47, Issue 3, 2010, Pages 542-545

  Mestek, Michael L ^a   Weil, Brian R ^a   Greiner, Jared J ^a   Westby, Christian M ^a   DeSouza, Christopher A ^a,b   Stauffer, Brian L ^a,b,c  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c DENVER HEALTH MEDICAL CENTER   (United States)

Author keywords

Endothelial function; Low bone mineral density; Osteopenia; Postmenopausal women; Vasoconstriction

Indexed keywords

CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN 1;

ADULT; ARTICLE; BLOOD VESSEL TONE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOREARM BLOOD FLOW; HUMAN; LUMBAR SPINE; OSTEOPENIA; POSTMENOPAUSE; PROTEIN FUNCTION; VASOCONSTRICTION;

ANTIHYPERTENSIVE AGENTS; BONE DENSITY; BONE DISEASES, METABOLIC; ENDOTHELIN-1; FEMALE; HEMODYNAMICS; HUMANS; MIDDLE AGED; MUSCLE TONUS; MUSCLE, SMOOTH, VASCULAR; PEPTIDES, CYCLIC; POSTMENOPAUSE; RECEPTORS, ENDOTHELIN; REGIONAL BLOOD FLOW; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 77955841959     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2010.05.041     Document Type: Article

References (43)

1. Khosla S., Melton L.J. Clinical practice. Osteopenia. N Engl J Med 2007, 356:2293-2300.
2. Looker A.C., Melton L.J., Harris T.B., Borrud L.G., Shepherd J.A. Prevalence and Trends in Low Femur Bone Density Among Older US Adults: NHANES 2005-2006 Compared with NHANES III dagger. J Bone Miner Res 2009.
3. Jorgensen L., Engstad T., Jacobsen B.K. Bone mineral density in acute stroke patients: low bone mineral density may predict first stroke in women. Stroke 2001, 32:47-51.
4. Ness J., Aronow W.S. Comparison of prevalence of atherosclerotic vascular disease in postmenopausal women with osteoporosis or osteopenia versus without osteoporosis or osteopenia. Am J Cardiol 2006, 97:1427-1428.
5. von der Recke P., Hansen M.A., Hassager C. The association between low bone mass at the menopause and cardiovascular mortality. Am J Med 1999, 106:273-278.
6. Caballero A.E. Endothelial dysfunction in obesity and insulin resistance: a road to diabetes and heart disease. Obes Res 2003, 11:1278-1289.
7. Quyyumi A.A. Endothelial function in health and disease: new insights into the genesis of cardiovascular disease. Am J Med 1998, 105:32S-39S.
8. Sanada M., Taguchi A., Higashi Y., Tsuda M., Kodama I., Yoshizumi M., Ohama K. Forearm endothelial function and bone mineral loss in postmenopausal women. Atherosclerosis 2004, 176:387-392.
9. Cummings S.R., Bates D., Black D.M. Clinical use of bone densitometry: scientific review. JAMA 2002, 288:1889-1897.
10. Lohman T.G., Roche A.F., Martorell R. Anthropometric Standardization Reference Manual 1991, Human Kinetics, Champaign.
11. Stauffer B.L., Hoetzer G.L., Smith D.T., DeSouza C.A. Plasma C-reactive protein is not elevated in physically active postmenopausal women taking hormone replacement therapy. J Appl Physiol 2004, 96:143-148.
12. Cardillo C., Campia U., Bryant M.B., Panza J.A. Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation 2002, 106:1783-1787.
13. Cardillo C., Kilcoyne C.M., Waclawiw M., Cannon R.O., Panza J.A. Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension 1999, 33:753-758.
14. Barengolts E.I., Berman M., Kukreja S.C., Kouznetsova T., Lin C., Chomka E.V. Osteoporosis and coronary atherosclerosis in asymptomatic postmenopausal women. Calcif Tissue Int 1998, 62:209-213.
15. Kelly J.J., Whitworth J.A. Endothelin-1 as a mediator in cardiovascular disease. Clin Exp Pharmacol Physiol 1999, 26:158-161.
16. Gulhan I., Kebapcilar L., Alacacioglu A., Bilgili S., Kume T., Aytac B., Gunaydin R. Postmenopausal women with osteoporosis may be associated with high endothelin-1. Gynecol Endocrinol 2009, 25:674-678.
17. Lekontseva ON, Chakrabarti S, Davidge ST. Endothelin in the female vasculature: a role in aging? Am J Physiol Regul Integr Comp Physiol.
18. Rosano G.M., Gebara O., Sheiban I., Silvestri A., Wajngarten M., Vitale C., Aldrighi J.M., Ramires A.F., Fini M., Mercuro G. Acute administration of 17beta-estradiol reduces endothelin-1 release during pacing-induced ischemia. Int J Cardiol 2007, 116:34-39.
19. de Kraker A.T., Kenemans P., Smolders R.G., Kroeks M.V., van der Mooren M.J. Short-term effects of two continuous combined oestrogen-progestogen therapies on several cardiovascular risk markers in healthy postmenopausal women: a randomised controlled trial. Eur J Obstet Gynecol Reprod Biol 2009, 142:139-144.
20. Maffei S., Mercuri A., Zucchelli G.C., Vassalle C. Estrogen therapy effects on different vasoactive factors in recent postmenopausal healthy women. Int J Cardiol 2006, 107:194-199.
21. Muratli H.H., Celebi L., Hapa O., Bicimoglu A. Comparison of plasma endothelin levels between osteoporotic, osteopenic and normal subjects. BMC Musculoskelet Disord 2005, 6:49.
22. Chang J.M., Kuo M.C., Chen H.M., Lee C.H., Lai Y.H., Chen H.C., Hwang S.J. Endothelin-1 regulates parathyroid hormone expression of human parathyroid cells. Clin Nephrol 2006, 66:25-31.
23. Chang J.M., Lai Y.H., Tsai J.H. Interaction between extracellular calcium and endothelin-1 influences parathyroid hormone secretion from bovine parathyroid cells through the increase in intracellular calcium. Miner Electrolyte Metab 1997, 23:113-120.
24. Fujii Y., Tomic M., Stojilkovic S.S., Iida T., Brandi M.L., Ogino Y., Sakaguchi K. Effects of endothelin-1 on Ca2+ signaling and secretion in parathyroid cells. J Bone Miner Res 1995, 10:716-725.
25. Stern P.H., Tatrai A., Semler D.E., Lee S.K., Lakatos P., Strieleman P.J., Tarjan G., Sanders J.L. Endothelin receptors, second messengers, and actions in bone. J Nutr 1995, 125:2028S-2032S.
26. Tatrai A., Foster S., Lakatos P., Shankar G., Stern P.H. Endothelin-1 actions on resorption, collagen and noncollagen protein synthesis, and phosphatidylinositol turnover in bone organ cultures. Endocrinology 1992, 131:603-607.
27. von Schroeder H.P., Veillette C.J., Payandeh J., Qureshi A., Heersche J.N. Endothelin-1 promotes osteoprogenitor proliferation and differentiation in fetal rat calvarial cell cultures. Bone 2003, 33:673-684.
28. Haliloglu B., Aksungar F.B., Ilter E., Peker H., Akin F.T., Ozekici U. Relationship between bone mineral density, bone turnover markers and homocysteine, folate and vitamin B12 levels in postmenopausal women. Arch Gynecol Obstet 2009.
29. Cohen-Solal M.E., Graulet A.M., Denne M.A., Gueris J., Baylink D., de Vernejoul M.C. Peripheral monocyte culture supernatants of menopausal women can induce bone resorption: involvement of cytokines. J Clin Endocrinol Metab 1993, 77:1648-1653.
30. Verma S., Li S.H., Badiwala M.V., Weisel R.D., Fedak P.W., Li R.K., Dhillon B., Mickle D.A. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002, 105:1890-1896.
31. Bismar H., Diel I., Ziegler R., Pfeilschifter J. Increased cytokine secretion by human bone marrow cells after menopause or discontinuation of estrogen replacement. J Clin Endocrinol Metab 1995, 80:3351-3355.
32. Patel J.N., Jager A., Schalkwijk C., Corder R., Douthwaite J.A., Yudkin J.S., Coppack S.W., Stehouwer C.D. Effects of tumour necrosis factor-alpha in the human forearm: blood flow and endothelin-1 release. Clin Sci (Lond) 2002, 103:409-415.
33. Haug C., Schmid-Kotsas A., Zorn U., Schuett S., Gross H.J., Gruenert A., Bachem M.G. Endothelin-1 synthesis and endothelin B receptor expression in human coronary artery smooth muscle cells and monocyte-derived macrophages is up-regulated by low density lipoproteins. J Mol Cell Cardiol 2001, 33:1701-1712.
34. Pollock D.M., Pollock J.S. Endothelin and oxidative stress in the vascular system. Curr Vasc Pharmacol 2005, 3:365-367.
35. Mody N., Parhami F., Sarafian T.A., Demer L.L. Oxidative stress modulates osteoblastic differentiation of vascular and bone cells. Free Radic Biol Med 2001, 31:509-519.
36. Signorelli S.S., Neri S., Sciacchitano S., Pino L.D., Costa M.P., Marchese G., Celotta G., Cassibba N., Pennisi G., Caschetto S. Behaviour of some indicators of oxidative stress in postmenopausal and fertile women. Maturitas 2006, 53:77-82.
37. White RE, Gerrity R, Barman SA, Han G. Estrogen and oxidative stress: A novel mechanism that may increase the risk for cardiovascular disease in women. Steroids.
38. Thijssen D.H., Ellenkamp R., Kooijman M., Pickkers P., Rongen G.A., Hopman M.T., Smits P. A causal role for endothelin-1 in the vascular adaptation to skeletal muscle deconditioning in spinal cord injury. Arterioscler Thromb Vasc Biol 2007, 27:325-331.
39. Wray D.W., Nishiyama S.K., Donato A.J., Sander M., Wagner P.D., Richardson R.S. Endothelin-1-mediated vasoconstriction at rest and during dynamic exercise in healthy humans. Am J Physiol Heart Circ Physiol 2007, 293:H2550-H2556.
40. Gossl M., Mitchell A., Lerman A. Opazo Saez A, Schafers RF, Erbel R, Philipp T, Wenzel RR. Endothelin-B-receptor-selective antagonist inhibits endothelin-1 induced potentiation on the vasoconstriction to noradrenaline and angiotensin II. J Hypertens 2004, 22:1909-1916.
41. Mitchell A., Luckebergfeld B., Buhrmann S., Rushentsova U., Nurnberger J., Siffert W., Schafers R.F., Philipp T., Wenzel R.R. Effects of systemic endothelin A receptor antagonism in various vascular beds in men: in vivo interactions of the major blood pressure-regulating systems and associations with the GNB3 C825T polymorphism. Clin Pharmacol Ther 2004, 76:396-408.
42. Luscher T.F., Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000, 102:2434-2440.
43. Cardillo C., Kilcoyne C.M., Cannon R.O., Panza J.A. Interactions between nitric oxide and endothelin in the regulation of vascular tone of human resistance vessels in vivo. Hypertension 2000, 35:1237-1241.